Cargando…

Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches

Inflammatory bowel disease (IBD) is a complex heterogeneous disorder defined by recurring chronic inflammation of the gastrointestinal tract, attributed to a combination of factors including genetic susceptibility, altered immune response, a shift in microbial composition/microbial insults (infectio...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Reilly, Catherine, Mills, Susan, Rea, Mary C., Lavelle, Aonghus, Ghosh, Subrata, Hill, Colin, Ross, R. Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7615213/
https://www.ncbi.nlm.nih.gov/pubmed/37849974
http://dx.doi.org/10.20517/mrr.2023.41
_version_ 1785145787401895936
author O’Reilly, Catherine
Mills, Susan
Rea, Mary C.
Lavelle, Aonghus
Ghosh, Subrata
Hill, Colin
Ross, R. Paul
author_facet O’Reilly, Catherine
Mills, Susan
Rea, Mary C.
Lavelle, Aonghus
Ghosh, Subrata
Hill, Colin
Ross, R. Paul
author_sort O’Reilly, Catherine
collection PubMed
description Inflammatory bowel disease (IBD) is a complex heterogeneous disorder defined by recurring chronic inflammation of the gastrointestinal tract, attributed to a combination of factors including genetic susceptibility, altered immune response, a shift in microbial composition/microbial insults (infection/exposure), and environmental influences. Therapeutics generally used to treat IBD mainly focus on the immune response and include non-specific anti-inflammatory and immunosuppressive therapeutics and targeted therapeutics aimed at specific components of the immune system. Other therapies include exclusive enteral nutrition and emerging stem cell therapies. However, in recent years, scientists have begun to examine the interplay between these therapeutics and the gut microbiome, and we present this information here. Many of these therapeutics are associated with alterations to gut microbiome composition and functionality, often driving it toward a “healthier profile” and preclinical studies have revealed that such alterations can play an important role in therapeutic efficacy. The gut microbiome can also improve or hinder IBD therapeutic efficacy or generate undesirable metabolites. For certain IBD therapeutics, the microbiome composition, particularly before treatment, may serve as a biomarker of therapeutic efficacy. Utilising this information and manipulating the interactions between the gut microbiome and IBD therapeutics may enhance treatment outcomes in the future and bring about new opportunities for personalised, precision medicine.
format Online
Article
Text
id pubmed-7615213
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher OAE Publishing Inc.
record_format MEDLINE/PubMed
spelling pubmed-76152132023-12-02 Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches O’Reilly, Catherine Mills, Susan Rea, Mary C. Lavelle, Aonghus Ghosh, Subrata Hill, Colin Ross, R. Paul Microbiome Res Rep Review Inflammatory bowel disease (IBD) is a complex heterogeneous disorder defined by recurring chronic inflammation of the gastrointestinal tract, attributed to a combination of factors including genetic susceptibility, altered immune response, a shift in microbial composition/microbial insults (infection/exposure), and environmental influences. Therapeutics generally used to treat IBD mainly focus on the immune response and include non-specific anti-inflammatory and immunosuppressive therapeutics and targeted therapeutics aimed at specific components of the immune system. Other therapies include exclusive enteral nutrition and emerging stem cell therapies. However, in recent years, scientists have begun to examine the interplay between these therapeutics and the gut microbiome, and we present this information here. Many of these therapeutics are associated with alterations to gut microbiome composition and functionality, often driving it toward a “healthier profile” and preclinical studies have revealed that such alterations can play an important role in therapeutic efficacy. The gut microbiome can also improve or hinder IBD therapeutic efficacy or generate undesirable metabolites. For certain IBD therapeutics, the microbiome composition, particularly before treatment, may serve as a biomarker of therapeutic efficacy. Utilising this information and manipulating the interactions between the gut microbiome and IBD therapeutics may enhance treatment outcomes in the future and bring about new opportunities for personalised, precision medicine. OAE Publishing Inc. 2023-09-26 /pmc/articles/PMC7615213/ /pubmed/37849974 http://dx.doi.org/10.20517/mrr.2023.41 Text en © The Author(s) 2023. https://creativecommons.org/licenses/by/4.0/© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
O’Reilly, Catherine
Mills, Susan
Rea, Mary C.
Lavelle, Aonghus
Ghosh, Subrata
Hill, Colin
Ross, R. Paul
Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches
title Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches
title_full Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches
title_fullStr Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches
title_full_unstemmed Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches
title_short Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches
title_sort interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7615213/
https://www.ncbi.nlm.nih.gov/pubmed/37849974
http://dx.doi.org/10.20517/mrr.2023.41
work_keys_str_mv AT oreillycatherine interplaybetweeninflammatoryboweldiseasetherapeuticsandthegutmicrobiomerevealsopportunitiesfornoveltreatmentapproaches
AT millssusan interplaybetweeninflammatoryboweldiseasetherapeuticsandthegutmicrobiomerevealsopportunitiesfornoveltreatmentapproaches
AT reamaryc interplaybetweeninflammatoryboweldiseasetherapeuticsandthegutmicrobiomerevealsopportunitiesfornoveltreatmentapproaches
AT lavelleaonghus interplaybetweeninflammatoryboweldiseasetherapeuticsandthegutmicrobiomerevealsopportunitiesfornoveltreatmentapproaches
AT ghoshsubrata interplaybetweeninflammatoryboweldiseasetherapeuticsandthegutmicrobiomerevealsopportunitiesfornoveltreatmentapproaches
AT hillcolin interplaybetweeninflammatoryboweldiseasetherapeuticsandthegutmicrobiomerevealsopportunitiesfornoveltreatmentapproaches
AT rossrpaul interplaybetweeninflammatoryboweldiseasetherapeuticsandthegutmicrobiomerevealsopportunitiesfornoveltreatmentapproaches